None listed
Conditions
Brief summary
This study looks at the feasibility and potential benefits of exercise for women undergoing primary treatment for ovarian cancer. Who is it for? You can join this study if you have ovarian cancer and you are about to start your first or second cycle of adjuvant or neoadjuvant chemotherapy (a treatment given in addition to surgery to try to prevent a cancer from coming back) and if you live within approximately 30kms of Brisbane CBD. Trial details Participants will take part in a specially-designed exercise program, which includes low to moderate intensity walking, for around 30 minutes daily, over 18 weeks of chemotherapy. It will measure chemotherapy completion rates, fatigue, physical function and distress. Participants will be required to complete two questionnaires to measure these. Approximately 36% of women do not complete adjuvant chemotherapy for ovarian cancer due to treatment side-effects, in particular fatigue. Incomplete chemotherapy may result in poorer survival. In other cancer groups, exercise programs are effective for increasing functional capacity, relieving fatigue, distress and extending survival.
Interventions
low risk excercise intervention including low to moderate intensity walking, accumulating approximately 30 minutes daily, during 18 weeks of chemotherapy. Patients in this intervention will be undergoing first-line chemotherapy. Most ovarian cancer patients in Australia receive 6, 3 weekly cycles of intravenous carboplatin and paclitaxel as first-line chemotherapy. The length of time in between cycles will be 3 weeks i.e. women receiving first-line chemotherapy are generally administered agents
low risk excercise intervention including low to moderate intensity walking, accumulating approximately 30 minutes daily, during 18 weeks of chemotherapy. Patients in this intervention will be undergoing first-line chemotherapy. Most ovarian cancer patients in Australia receive 6, 3 weekly cycles of intravenous carboplatin and paclitaxel as first-line chemotherapy. The length of time in between cycles will be 3 weeks i.e. women receiving first-line chemotherapy are generally administered agents intravenously on day 1 of week 1, 4, 7, 10, 13 and 16.
Sponsors
Queensland Institute of Medical Research
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1 aged 18 years or more; 2 living in commuting distance from Brisbane hospitals; 3 with histologically or cytologically verified ovarian cancer; 4 about to start first or second cycle of adjuvant or neoadjuvant chemotherapy 5 able to read and complete the questionnaires and give informed consent
Exclusion criteria
1 Women with borderline ovarian tumours or who have had a prior malignancy within the last 5 years (excluding carcinoma in-situ of the cervix or basal cell carcinoma of the skin). 2 If it is considered unsafe for the patient to undertake a graded exercise programme.
Outcome results
None listed